Overview
With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs more >
Portfolio
Recent News
- Thu, Oct 11th, 2018 — H.I.G. BioHealth Partners Completes Sale of HyperBranch Medical Technology, Inc. to Stryker
- Mon, Aug 6th, 2018 — Symposium to Explore the Impact of Vascular Dissections on Critical Limb Ischemia Patients…
- Wed, Jul 11th, 2018 — CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan
- Wed, Jul 11th, 2018 — Intact Vascular Welcomes Publication of iDissection Classification Study Results in Journal…
- Mon, Jun 11th, 2018 — HyperBranch Medical Technology, Inc. Wins Jury Trial in Patent Infringement Lawsuit Filed…
- Tue, May 8th, 2018 — Apollo Endosurgery Establishes European Registry for Bariatric Flexible Endoscopic Suturing…
- Mon, May 7th, 2018 — CardioFocus® Announces FDA Approval of the Next-Generation HeartLight® Excalibur Balloon™…
- Mon, Apr 23rd, 2018 — Apollo Endosurgery Announces Approval of the New 12-month Weight Loss Balloon - ORBERA365™…
- Mon, Apr 16th, 2018 — Intact Vascular Announces $20 Million Series C Financing to Fund Company through PMA Approval…
- Mon, Apr 16th, 2018 — Intact Vascular Announces Enrollment Completion of the Tack Optimized Balloon Angioplasty…